1.Quadrantectomy and axillary node dissection in breast cancer after preoperative inductive chemotherapy.
Journal of the Korean Cancer Association 1992;24(6):840-847
No abstract available.
Breast Neoplasms*
;
Breast*
;
Drug Therapy*
2.The effect of inductive chemotherapy with FAC regimen on breast cancer.
Journal of the Korean Cancer Association 1991;23(4):783-789
No abstract available.
Breast Neoplasms*
;
Breast*
;
Drug Therapy*
3.Chemotherapy of breast cancer.
Korean Journal of Medicine 2000;58(5):497-509
No abstract available.
Breast Neoplasms*
;
Breast*
;
Drug Therapy*
4.Effectiveness of postoperative adjuvant treatment between radiation alone and chemotherapy plus radiation in locally advanced breast cancer.
Kyung Ran PARK ; John Kyu LOH JUHN ; Chang Ok SUH ; Gwi Eon KIM ; Eun Hee KOH ; Byung Soo KIM ; Kyung Sik LEE
Journal of the Korean Cancer Association 1991;23(1):107-119
No abstract available.
Breast Neoplasms*
;
Breast*
;
Drug Therapy*
5.Systemic adjuvant therapy in breast cancer.
Jin Hee AHN ; Sung Bae KIM ; Woo Kun KIM
Korean Journal of Medicine 2005;69(3):243-254
No abstract available.
Breast Neoplasms*
;
Breast*
;
Drug Therapy
;
Neoadjuvant Therapy
6.Mono- and Combination Chemotherapy for Metastatic Breast Cancer: An Increamental Step Forward.
Journal of Korean Breast Cancer Society 2003;6(3):137-140
No abstract available.
Breast Neoplasms*
;
Breast*
;
Drug Therapy, Combination*
7.The effect of adjuvant CMF(cyclophosphamide, methotrexate, 5-FU) chemotherapy of breast cancer.
Joon PARK ; Jung Han YOON ; Young Jong JEGAL
Journal of the Korean Cancer Association 1993;25(6):928-934
No abstract available.
Breast Neoplasms*
;
Breast*
;
Drug Therapy*
;
Methotrexate*
8.Clinical and pathologic tumor response following response-guided neoadjuvant chemotherapy for locally-advanced breast cancer in a Tertiary Hospital Breast Center in the Philippines
Shiela S. Macalindong ; Ralph Lazarus R. Rapacon
Philippine Journal of Surgical Specialties 2024;79(1):42-53
Rationale/Objective:
Neoadjuvant chemotherapy (NAC) is
recommended for locally-advanced breast cancer (LABC) to improve
resectability and provide in-vivo tumor response assessment. This
study aimed to describe the clinical and pathologic tumor response
of LABC patients after response-guided NAC.
Methods:
This is a retrospective cohort analysis of 128 LABC patients
who underwent NAC using sequential doxorubicin/cyclophosphamide
(AC) – docetaxel (T) regimen at the Philippine General Hospital
Breast Care Center. Clinical and pathologic response rates were
analyzed according to clinicopathologic variables including tumor
intrinsic subtype.
Results:
Objective clinical response (complete and partial) was
observed in 88% (111/128) of patients with 11% (14/128) achieving
pathologic complete response (pCR). The hormone receptor-negative/
Her2-enriched (HR-/Her2+) subtype had the highest pCR rate (23.5%)
followed by triple negative subtype (HR-/Her2-) at 19%. The hormone
receptor-positive/Her2-positive (HR+/Her2+) subtype had the lowest
pCR (4.7%). Two patients with initial poor response to AC but had
good response upon shifting to T achieved pCR. Twelve patients
(9.4%) had poor response to AC and T chemotherapy. Patients who
were pre-menopausal (p=0.04), had ductal histology (p=0.03), with
a HR-/Her2- (p=0.002) or HR+/Her2+ subtype (p=0.03) had good
response to AC. Intrinsic subtype was not significantly associated
with treatment response in those who received docetaxel. There was
strong association between the pathologic and clinical responses
(Spearman’s Rho score 0.69, p-value <0.0001).
Conclusion
Clinical and pathologic response to NAC was highly
dependent on tumor subtype. Clinical response was predictive of
pathologic response. Response-guided NAC allowed direct and early
evaluation of tumor treatment response that allowed for treatment
modifications.
Breast Neoplasms
;
Neoadjuvant Therapy
;
Drug Therapy
9.Breast Cancer with Leptomeningeal Metastasis.
Ho Kyun LEE ; Il Joo HA ; Jung Chul KIM ; Soo Jin Na CHOI ; Jung Han YOON ; Young Jong JAEGAL
Journal of the Korean Surgical Society 2004;66(3):239-242
Leptomeningeal metastsis (LM) is a disease where the tumor cells involves the leptomeninges. Breast cancer, of all solid tumors, is the primary tumor most frequently associated with leptomeningeal metastasis. Leptomeningeal metastasis originating from breast cancer is usually detected at an advanced stage, so its evaluation and aggressive treatment are difficult. Leptomeningeal metastasis, from solid tumors, has been reported to inexorably lead to death within 4 to 6 weeks if left untreated. Intrathecal or Intraventricular chemotherapy and radiotherapy are the mainstays of treatment. Even though controversial, systemic chemotherapy, with regional radiotherapy, can also improve the neurological outcome and survival, without neurotoxicity. Here, two patients with leptomeningeal metastasis, originating from breast cancer, their clinical course and treatment modalities are reported.
Breast Neoplasms*
;
Breast*
;
Drug Therapy
;
Humans
;
Neoplasm Metastasis*
;
Radiotherapy
10.Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide.
Jungsil RO ; Fiona Tsui Fen CHENG ; Virote SRIURANPONG ; Antonio VILLALON ; B K SMRUTI ; Janice TSANG ; Yoon Sim YAP
Journal of Breast Cancer 2016;19(1):8-17
Eribulin, an antimicrotubule chemotherapeutic agent, is approved for the treatment of pretreated metastatic breast cancer (mBC) based on the positive outcomes of phase II and phase III clinical trials, which enrolled mainly Western patients. Eribulin has recently been approved in an increasing number of Asian countries; however, there is limited clinical experience in using the drug in certain countries. Therefore, we established an Asian working group to provide practical guidance for eribulin use based on our clinical experience. This paper summarizes the key clinical trials, and the management recommendations for the reported adverse events (AEs) of eribulin in mBC treatment, with an emphasis on those that are relevant to Asian patients, followed by further elaboration of our eribulin clinical experience. It is anticipated that this clinical practice guide will improve the management of AEs resulting from eribulin treatment, which will ensure that patients receive the maximum treatment benefit.
Asian Continental Ancestry Group
;
Breast Neoplasms*
;
Breast*
;
Drug Therapy
;
Humans